The Sonoma Pharmaceuticals Inc. (SNOA) shares are trading at higher $6.46 and the avg recommendation for the stock is Moderate Buy.
To add more color to this target, the company’s high over the last year is $19.60 and the low is $3.33. Over the last 52 weeks, SNOA is down -67.04% while the S&P 500 is down -0.63%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
In the last quarter, SNOA reported a profit of $1.51 million. Sonoma Pharmaceuticals Inc. also saw revenues increase to $4.58 million. In addition, SNOA has free cash flow of -$4.8 million as of 03-2020. The company’s EBITDA came in at -$2.66 million which compares well with its peers.
SNOA booked profit margins of -15.60%, its Return on Equity (ROE) is -28.30%, and its Return on Assets is -18.40%. All told, it is clear that, SNOA needs to be on your watchlist.
Find out when SNOA reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. SNOA has a short ratio of 0.03 and outstanding shares of 1.77M.
SNOA has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 46020.0 and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -1.87. Sonoma Pharmaceuticals Inc. SNOA also noted assets of $14.56 million at the end of the last quarter. Investors should also keep an eye on sector updates as SNOA has historically followed its peers on positive news.
All told, Sonoma Pharmaceuticals Inc. SNOA has strung together solid data and demonstrated underlying fundamentals. At its current valuation, SNOA represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Sonoma Pharmaceuticals Inc. SNOA is now commanding a market cap of 13.18M. SNOA is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of SNOA stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in SNOA, either long or short, and we have not been compensated for this article.